Modern Cosmetic Science

Unveiling Beauty's Tech Frontier: Exploring the Latest Breakthroughs in Modern Cosmetic Science.


Mohs micrographic surgery for periocular skin cancer: a single-institution experience

Shi, Kevin, Wang, Laura, Srivastava, Divya ORCID: 0000-0001-5135-3592 and Nijhawan, Rajiv I.


Mohs micrographic surgery for periocular skin cancer: a single-institution experience.

Archives of Dermatological Research, 315 (5).
1181 – 1186.
ISSN 0340-3696

Full text not available from this repository.


Periocular skin cancers require both effective and tissue-sparing treatment to minimize morbidity and preserve eyelid and lacrimal system function. We aim to define outcomes of periocular tumors treated with Mohs micrographic surgery (MMS) and factors associated with poor outcomes after surgery. This is a retrospective cohort study of all periocular tumors treated with MMS at an academic, large metropolitan-based referral center from January 1, 2013 to December 31, 2018. For 316 tumors from 307 patients, 75.3% of cases were basal cell carcinoma (BCC) (n = 238), 20.9% were squamous cell carcinoma (SCC) (n = 66), 2.5% were melanoma (n = 8), and 1.3% were primary adnexal carcinoma (n = 4). Over a mean follow-up of 47 months (range 12–108 months), local recurrence of two BCCs was observed. There were no recurrences for SCC, adnexal carcinoma, or melanoma. For BCC, previously treated tumors had higher risk for recurrence after MMS. AJCC 8 T stage was not associated with poor outcomes after MMS for periocular carcinoma or melanoma. Mohs micrographic surgery offers excellent cure rates for periocular cutaneous tumors. For basal cell carcinoma, previously treated lesions were associated with additional recurrence after MMS.

Item Type: Article

Official URL:
Additional Information: © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Divisions: Health Policy
Subjects: R Medicine > RD Surgery
R Medicine > RL Dermatology
Date Deposited: 23 Apr 2024 10:39
Last Modified: 23 Apr 2024 10:45

Actions (login required)

View Item View Item


Your email address will not be published. Required fields are marked *